ArticleNPJ precision oncology2026
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.
Gerald Falchook et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it